Perspective of placenta derived mesenchymal stem cells in acute liver failure
Authors:
Open Access
- 24 May 2020
- journal article
- review article
- Published by Springer Nature in Cell & Bioscience
- Vol. 10 (1) , 1-11
Abstract
Acute Liver failure (ALF) is a life-threatening disease and is determined by coagulopathy (with INR ≥ 1.5) and hepatic encephalopathy as a result of severe liver injury in patients without preexisting liver disease. Since there are problems with liver transplantation including lack of donors, use of immunosuppressive drugs, and high costs of this process, new therapeutic approaches alongside current treatments are needed. The placenta is a tissue that is normally discarded after childbirth. On the other hand, human placenta is a rich source of mesenchymal stem cells (MSCs), which is easily available, without moral problems, and its derived cells are less affected by age and environmental factors. Therefore, placenta-derived mesenchymal stem cells (PD-MSCs) can be considered as an allogeneic source for liver disease. Considering the studies on MSCs and their effects on various diseases, it can be stated that MSCs are among the most important agents to be used for novel future therapies of liver diseases. In this paper, we will investigate the effects of mesenchymal stem cells through migration and immigration to the site of injury, cell-to-cell contact, immunomodulatory effects, and secretory factors in ALF.Keywords
This publication has 163 references indexed in Scilit:
- In Vivo Tracking and Comparison of the Therapeutic Effects of MSCs and HSCs for Liver InjuryPLOS ONE, 2013
- Introduction to the revised American Association for the Study of Liver Diseases position paper on acute liver failure 2011Hepatology, 2012
- Cell Therapies for Liver DiseasesLiver Transplantation, 2011
- Human chorionic-plate-derived mesenchymal stem cells and Wharton’s jelly-derived mesenchymal stem cells: a comparative analysis of their potential as placenta-derived stem cellsCell and tissue research, 2011
- Comparison of Human Placenta- and Bone Marrow–Derived Multipotent Mesenchymal Stem CellsStem Cells and Development, 2008
- Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing mediumBone Marrow Transplantation, 2008
- Mesenchymal Stem Cells: Revisiting History, Concepts, and AssaysCell Stem Cell, 2008
- Immunomodulation of activated hepatic stellate cells by mesenchymal stem cellsBiochemical and Biophysical Research Communications, 2007
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- AASLD position paperHepatology, 2005